Skip to main content

A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433

Active, not recruiting · Phase 3 · NCT03345823

Conditions: Crohn's Disease

At a glance

Research payments reported, 2025
$537,176
U.S. investigators named
37
Sites paid
37
Planned or actual enrollment
747

About the trial

Sponsor
AbbVie
Tested
Upadacitinib (drug), Placebo for Upadacitinib (drug)
Dates
Started 2018-03-21; completion 2027-09
Results posted
Not yet

A multicenter study to evaluate the efficacy and safety of maintenance and long-term treatment administration of upadacitinib, an orally administered Janus kinase 1 inhibitor, in adult participants with Crohn's Disease.

From ClinicalTrials.gov, last updated 2026-04-09. Full record, eligibility and contacts (opens in a new tab)

Industry funding

AbbVie Inc. reported $537,176 in research payments for this study in 2025 (160 payments).

Products named: Rinvoq

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.